Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Governance document

Draft print and archival format for Institute documents

Consultation on the print and archival format for Institute documents: what a printed copy must carry so that it remains checkable when detached from the site, and what an archival copy must preserve.

Document identifier
CEI-CP-037
Series
Public comment period
Version
1.0
Published
02 May 2025
Last reviewed
02 May 2025
Next review
02 May 2026
Identifier
10.71829/cei.cp.37
Certainty
Not rated
Cycle
2025 Q1
Window
04 Feb 2025 – 05 Apr 2025
Status
Closed
Submissions
18

§1Consultation and window

§1.1Window

Opened
4 February 2025
Closed
5 April 2025
Duration
60 days
Status
Closed — the disposition is published
Document under consultation
Governance document
Submissions received
18

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Does the proposed print format carry enough for a printed copy to be traced back to its source, including the version and the date it was retrieved?
  2. Should a printed copy carry the full reference list, or a link to it?
  3. Is the archival format robust to the loss of the stylesheet, so that a preserved copy remains readable?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The format was ratified with amendments. A printed copy carries the identifier, version, publication date and retrieval date in a fixed position, and carries the full reference list, after respondents pointed out that a printed copy referring to an external list is a document a reader cannot check.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.